共 50 条
Recombinant high-density lipoproteins and their use in cardiovascular diseases
被引:17
|作者:
Cao, Yi-ni
[1
,2
]
Xu, Lu
[1
,2
]
Han, Ying-chun
[1
,2
]
Wang, Yu-nan
[1
,2
]
Liu, George
[1
,2
]
Qi, Rong
[1
,2
]
机构:
[1] Peking Univ, Hlth Sci Ctr, Inst Cardiovasc Sci, 38 Xueyuan Rd, Beijing 100191, Peoples R China
[2] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China
基金:
中国国家自然科学基金;
关键词:
APOLIPOPROTEIN-A-I;
AMPHIPATHIC HELICAL PEPTIDE;
LECITHIN-CHOLESTEROL ACYLTRANSFERASE;
HERITABLE HYPERLIPIDEMIC RABBITS;
RANDOMIZED CONTROLLED-TRIAL;
APOA-I;
MIMETIC PEPTIDE;
ANTIINFLAMMATORY PROPERTIES;
CORONARY ATHEROSCLEROSIS;
BIOLOGICAL-PROPERTIES;
D O I:
10.1016/j.drudis.2016.08.010
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.
引用
收藏
页码:180 / 185
页数:6
相关论文